News
// 49 Results
-
MERZ THERAPEUTICS TO PRESENT ROBUST DATA ON XEOMIN® (INCOBOTULINUMTOXINA) AT TOXINS 2022 CONFERENCE
RALEIGH, N.C. /
Merz Therapeutics announced today the presentation of data from 10 accepted abstracts on XEOMIN® (incobotulinumtoxinA) at TOXINS 2022: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins, taking place in New Orleans, LA July 27-30.
-
MERZ THERAPEUTICS DONATES $100,000 TO SUPPORT CONSTRUCTION OF NEW REHABILITATION CENTER AT UNIVERSITY OF NORTH CAROLINA
Raleigh, N.C. /
Merz Therapeutics announced today its U.S. organization has made a $100,000 donation to the University of North Carolina (UNC) Health Foundation to assist in funding construction and capital expenses of UNC Health’s new Acute Inpatient Rehabilitation Center (the “AIR Center”), scheduled to open in Hillsborough, N.C. in February 2022.
-
XEOMIN® (INCOBOTULINUMTOXINA) SAFETY AND EFFICACY DATA FOR TREATMENT OF PEDIATRIC CHRONIC SIALORRHEA PUBLISHED IN NEUROLOGY
Raleigh, N.C. /
Merz Therapeutics announced today the online publication of the article “SIPEXI: Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children” in Neurology, the premier peer-reviewed journal for clinical neurology research.
-
MERZ THERAPEUTICS TO PRESENT KEY DATA ON XEOMIN® (incobotulinumtoxinA) AT TOXINS 2021 VIRTUAL CONFERENCE
RALEIGH, N.C. /
Merz Therapeutics announced today the presentation of data from 18 accepted abstracts on XEOMIN® (incobotulinumtoxinA) at TOXINS 2021: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins, taking place virtually January 16 and 17.
-
INFOGRAPHIC: XEOMIN® (incobotulinumtoxinA) PEDIATRIC CHRONIC SIALORRHEA
RALEIGH, N.C. /
XEOMIN® (incobotulinumtoxinA) is now approved by the FDA for the treatment of patients aged 2 years and older with chronic sialorrhea, or drooling. XEOMIN is the first and only FDA-approved neuromodulator with this indication. Download our infographic detailing our latest approval.
-
FDA APPROVES PEDIATRIC INDICATION FOR XEOMIN® (incobotulinumtoxinA) FOR THE TREATMENT OF CHRONIC SIALORRHEA
RALEIGH, N.C. /
Merz Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for XEOMIN® (incobotulinumtoxinA) for the treatment of patients aged 2 years and older with chronic sialorrhea, or drooling. XEOMIN is the first and only FDA-approved neuromodulator with this indication and was granted a priority review designation upon acceptance by the FDA.
-
FDA APPROVES FIRST PEDIATRIC INDICATION FOR XEOMIN® (incobotulinumtoxinA) FOR THE TREATMENT OF UPPER LIMB SPASTICITY, EXCLUDING SPASTICITY CAUSED BY CEREBRAL PALSY
RALEIGH, N.C. /
Merz Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the first pediatric indication for XEOMIN® (incobotulinumtoxinA), for the treatment of patients aged 2 years and older with upper limb spasticity, excluding spasticity caused by cerebral palsy.
-
Xeomin® (IncobotulinumtoxinA) Celebrates 10 Years of Meeting the Needs of Patients Suffering from Movement Disorders
RALEIGH, N.C. /
Merz Therapeutics is commemorating today the 10th anniversary of the first therapeutic approval of XEOMIN by the U.S. Food and Drug Administration.
-
MERZ FORMS FULLY FOCUSED GLOBAL MEDICAL AESTHETICS BUSINESS: MERZ AESTHETICS
RALEIGH, N.C. /
Merz, a global leader in the field of aesthetics and neurotoxins, today announced plans to reorganize into three independently operating businesses: medical aesthetics, therapeutics and consumer care.
-
FDA Approves Broadened Indication for XEOMIN® (incobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in Adult Patients
RALEIGH, N.C. /
Merz Americas announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN®(incobotulinumtoxinA), broadening its indication to be a first-line treatment of blepharospasm (involuntary blinking) in adult patients.
-
Merz presents data confirming the long-term efficacy and safety of Xeomin® (incobotulinumtoxina) for sialorrhea
RALEIGH, N.C. /
Merz today announced long-term results from a Phase 3 extension study of XEOMIN® (incobotulinumtoxinA) for the treatment of adults with chronic sialorrhea, also known as excessive drooling. Results were presented at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly being held October 25-28 in Orlando, FL.
-
Merz Named “Top Aesthetics Company” by Aesthetic Everything® for Second Year in a Row
RALEIGH, N.C. /
For the second year in a row, Merz has been recognized as the “Top Aesthetics Company” by Aesthetic Everything® and Bob Rhatigan has been named the “Top Aesthetics CEO.” As part of the annual Aesthetic and Cosmetic Medicine Awards, Merz executives and products were also recognized with 14 additional award wins – 16 total wins overall.
-
Merz presents key findings showcasing five-year effectiveness of cellfina® on cellulite removal and physician recognition of ultherapy® as gold standard treatment
RALEIGH, N.C. /
Merz, a global leader in medical aesthetics, presented five-year follow-up data on Cellfina® System, which showed that a single treatment improved the appearance of cellulite on the thighs and buttocks for five years, building upon a previous study, which showed results lasting at least three years
-
Merz Names Kristina Yu-Isenberg, Ph.D., Vice President of Medical Affairs North America
RALEIGH, N.C. /
Merz today announced Kristina Yu-Isenberg, Ph.D., M.P.H, R.Ph., has been named Vice President of Medical Affairs North America, effective immediately. Dr. Yu-Isenberg oversees medical affairs in North America and is located in the Merz North America headquarters in Raleigh, North Carolina.
-
Merz Creates Americas Region, Expands Bob Rhatigan’s Leadership Role
Frankfurt, Germany /
Merz, a global leader in medical aesthetics and neurotoxins, today announced the appointment of Bob Rhatigan as Chief Executive Officer – Americas. Expanding on his leadership of Merz’s North American business, Mr. Rhatigan will now assume responsibility for Latin America as well and will oversee the overall commercial strategy for the newly-created Americas Region. In addition, Frank Brandt-Pollmann has been promoted to Area Vice President – Latin America...
-
FDA Approves XEOMIN® (incobotulinumtoxinA) For Adult Patients with Sialorrhea
RALEIGH, N.C. /
Merz North America announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN® (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, in adult patients. XEOMIN is the first and only neurotoxin with this approved indication in the U.S.
-
Merz North America Promotes Alana Sine to Chief Financial Officer
RALEIGH, N.C. /
Merz North America today announced the appointment of Alana Sine to Chief Financial Officer (CFO), Merz North America. Sine has served as interim CFO since March 2018.
-
Merz Products Recognized as Best-In-Class by NewBeauty, THE European Aesthetic Guide and InStyle Magazine
RALEIGH, N.C. /
Merz announced today that Ultherapy®, Radiesse® and Cellfina® have been named the best “In-Office Treatments” by NewBeauty Magazine. In addition, Cellfina® was recognized as the “Best Non-Surgical Body Shaping Device” by THE European Aesthetic Guide. Neocutis® Lumière® and Lumière® Riche were named “Best Beauty Buys” by InStyle Magazine...
-
New National Study Reveals the Need to Educate About Tattoo Removal Options
RALEIGH, N.C. /
Merz North America today announced the results of a survey, conducted by Wakefield Research, to better understand public perceptions of tattoo removal. The survey results found that more than four in five adults with (86%) and without (82%) tattoos have misconceptions about tattoo removal...
-
FDA Accepts for Filing Supplemental Biologics License Application (sBLA) for Xeomin® (incobotulinumtoxinA) in Adult Patients with Sialorrhea
RALEIGH, N.C. /
Merz North America announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (sBLA) for Xeomin® (incobotulinumtoxinA) for the treatment of chronic sialorrhea (excessive drooling) due to Parkinson’s Disease or other neurologic disorders in adult patients...
-
Merz North America to Highlight Treatments at American Academy of Dermatology Annual Meeting
RALEIGH, N.C. /
Merz North America announced today that Merz aesthetics products including Xeomin®, Cellfina®, Radiesse®, Ultherapy® and DeScribe® PFD Patch will be featured in oral and online ePoster presentations at the American Academy of Dermatology (AAD) annual meeting in San Diego, CA, taking place February 16-20, 2018...
-
Merz Names Terri L. Phillips, M.D., Vice President and Head of Global Medical Affairs
RALEIGH, N.C. /
Merz today announced that Terri L. Phillips, M.D., F.A.A.P., has been named Vice President and Head of Global Medical Affairs, effective January 2, 2018. Dr. Phillips will oversee the global medical affairs team and will be located in the Merz North America headquarters in Raleigh, N.C...
-
Merz North America Announces New FDA Clearance for Describe® PFD Patch. Describe®, the first and only accessory for laser-assisted tattoo removal, is cleared for use with additional lasers and wavelengths
RALEIGH, N.C. /
Merz North America announced today the DESCRIBE® PFD Patch has been cleared by the Food and Drug Administration (FDA) for all commonly used lasers for tattoo removal.
-
Ultherapy® Named "Best Skin Tightening Device" by The Aesthetic Guide
RALEIGH, N.C. /
Merz announced today Ultherapy® has been named the "Best Skin Tightening Device" by THE Aesthetic Guide, a leading aesthetic industry publication. Ultherapy® is the only FDA- cleared, non-invasive procedure that lifts and tightens the neck, chin and brow, and improves lines and wrinkles on the chest.
-
MERZ NAMED THE TOP AESTHETICS COMPANY BY AESTHETIC EVERYTHING®. Merz North America CEO Bob Rhatigan named the Top Aesthetics CEO Cellfina® and Ultherapy® Also Recognized as Top Procedures
RALEIGH, N.C. /
Merz North America, Inc. announced today that Merz has been recognized by Aesthetic Everything® as the Top Aesthetics Company and the winner of four other 2017 Diamond Crystal Awards, including the recognition of Cellfina® as the Top Minimally Invasive Procedure and Ultherapy® as a Top Non-Surgical Procedure in the industry.
-
NEOCUTIS® RECEIVES ITS 16th INSTYLE “BEST BEAUTY BUY” AWARD. Lumière® Recognized by InStyle as “Best Eye Cream”
RALEIGH, N.C. /
Merz Aesthetics, a division of Merz North America, announced today that NEOCUTIS® Lumière was named an InStyle 2017 "Best Beauty Buy" award winner for "Best Eye Cream."
-
MERZ AESTHETICS ANNOUNCES LAUNCH OF MEDERMA® QUICK DRY OIL AND MEDERMA® SPEZIAL
RALEIGH, N.C. /
Merz Aesthetics, a division of Merz North America announces the U.S. launch of Mederma® Quick Dry Oil, a unique, fast-absorbing multipurpose oil formulated without artificial dyes, colors, perfumes, parabens or mineral oils that works to help diminish the appearance of scars, stretch marks, uneven skin tone and dry skin, and Mederma® Spezial, a unique collection of cream mousses and dietary supplements formulated to promote healthy skin, hair and nails.
-
Merz Appoints Bob Rhatigan as President and Chief Executive Officer in North America. Patrick Urban also named Chief Commercial Officer
Frankfurt /
Merz Pharma, a global leader in aesthetics and neurotoxins, today announced the appointment of Bob Rhatigan as President and Chief Executive Officer (CEO) of Merz North America and Patrick Urban as Chief Commercial Officer
-
ULTHERAPY® AND CELLFINA® SYSTEM RECOGNIZED AS BEST-IN-CLASS TREATMENTS IN NEWBEAUTY’S ANNUAL BEAUTY CHOICE AWARDS
RALEIGH, N.C. /
Merz Aesthetics, a division of Merz North America, announced today that Ultherapy® and the Cellfina® System have been recognized by NewBeauty readers and editors in their 2017 Beauty Choice Awards as best-in-class.
-
MERZ AESTHETICS CELEBRATES THE 10th ANNIVERSARY OF RADIESSE. Radiesse Marks Key Milestone with Revealing Patient Survey Results
RALEIGH, N.C. /
Merz Aesthetics, a division of Merz North America (U.S. affiliate of Merz Pharma Group) announced the 10-year anniversary of the launch of their flagship brand, Radiesse . Radiesse is a volumizing filler used in more than 60 countries, and is unique in its ability to provide instant lift and stimulate the natural production of collagen with just one injection. More than 6 million syringes have been purchased by professionals worldwide over the past ten years.
-
MERZ AESTHETICS ANNOUNCES THREE YEAR FDA CLEARANCE FOR CELLFINA™ SYSTEM. Cellfina Earns Longest FDA Cleared Duration for a Cellulite Treatment
RALEIGH, N.C. /
Merz Aesthetics, a division of Merz North America (U.S. affiliate of the global Merz Pharma Group), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Cellfina™ System for the long-term improvement in the appearance of cellulite on the buttocks and thighs of adult females with no loss of benefit for up to 3 years.
-
NEOCUTIS® Receives O, The Oprah Magazine Fall Beauty 2016 “O-WARD”. MICRO•NIGHT® RICHE Rejuvenating Balm Recognized by O, The Oprah Magazine as Best Night Treatment for Sensitive Skin
RALEIGH, N.C. /
Merz Aesthetics, a division of Merz North America (US affiliate of the global Merz Pharma Group), announced today that NEOCUTIS MICRO•NIGHT® RICHE Rejuvenating Balm is an O, The Oprah Magazine Fall Beauty 2016 “O-Ward” winner for being a top performer in the Night Treatment category for sensitive skin.
-
MERZ ACQUIRES AESTHETICS MEDICAL DEVICE COMPANY ON LIGHT SCIENCES
RALEIGH, N.C. /
Merz North America announced today it has expanded its aesthetic portfolio through the acquisition of ON Light Sciences, Inc.
-
MERZ NEUROSCIENCES ANNOUNCES DATA PRESENTATIONS AT THE 9TH WORLD CONGRESS FOR NEUROREHABILITATION
RALEIGH, N.C. /
Merz Neurosciences, a division of Merz North America (US affiliate of the global Merz Pharma Group), today announced that Merz has two oral presentations at the 9th World Congress for Neurorehabilitation in Philadelphia, PA, including data for XEOMIN® (incobotulinumtoxinA) in the treatment of adult Upper Limb Spasticity (ULS), the indication for which Merz recently received FDA approval.
-
CELLFINA™ SYSTEM RECEIVES GOOD HOUSEKEEPING BEAUTY BREAKTHROUGH AWARD. Cellulite Treatment Named Best Body Solution
RALEIGH, N.C. /
Merz Aesthetics, a division of Merz North America (US affiliate of the global Merz Pharma Group), announced today that the Cellfina™ System has received the 2016 Good Housekeeping Best of Beauty Awards in the Body Solution category. Cellfina™ is the only FDA-cleared minimally invasive procedure clinically proven to improve the appearance of cellulite in the buttocks and thighs of adult females, for results that last at least two years, the longest duration cleared by the FDA. Winners are featured in the May 2016 issue of Good Housekeeping Magazine.
-
NEOCUTIS® RECEIVES ITS 15th InStyle ”BEST BEAUTY BUY” AWARD. Lumière® and Lumière Riche Recognized by InStyle as Best Eye Treatments
RALEIGH, N.C. /
Merz Aesthetics, a division of Merz North America (US affiliate of the global Merz Pharma Group), announced today that NEOCUTIS® Lumière and Lumière Riche were named InStyle 2016 “Best Beauty Buys” award winners for Best Eye Treatment and Best Eye Treatment for Dry Skin, respectively.
-
MERZ NEUROSCIENCES ANNOUNCES NEW SURVEY FINDINGS THAT SHOWCASE LACK OF AWARENESS OF UPPER LIMB SPASTICITY (ULS). More than 8 in 10 Americans Say They Have Never Heard of ULS
RALEIGH, N.C. /
Merz Neurosciences, a division of Merz North America (US affiliate of the global Merz Pharma Group), today announced findings from a new survey of more than 1,000 US adults, revealing that overall awareness of the signs and symptoms of adult Upper Limb Spasticity (ULS) is low among Americans.
-
CELLFINA™ SYSTEM LAUNCHES NATIONWIDE AT THE AMERICAN SOCIETY FOR AESTHETIC PLASTIC SURGERY. Data on New Treatment Also Being Presented At Annual Meeting
RALEIGH, N.C. /
Merz Aesthetics, a division of Merz North America (US affiliate of the global Merz Pharma Group) announced today that its Cellfina™ System will launch nationwide at the Annual Meeting for the American Society for Aesthetic Plastic Surgery in Las Vegas, NV. Cellfina is the only FDA-cleared, minimally invasive procedure clinically proven to improve the appearance of cellulite for results that last at least two years – the longest duration cleared by the FDA.
-
ULTHERAPY® AWARDED “BEST NONSURGICAL SKIN TIGHTENER” IN NEWBEAUTY’S ANNUAL BEAUTY CHOICE AWARDS. Ultherapy® Earns a Best of Beauty Award for the Third Year in a Row
RALEIGH, N.C. /
Merz Aesthetics, a division of Merz North America (US affiliate of the global Merz Pharma Group) announced today that Ultherapy® has been named “Best Nonsurgical Skin Tightener” in the 2016 Beauty Choice Awards.
-
NEOCUTIS® LAUNCHES MICRO•FIRM™ NECK & DÉCOLLETÉ REJUVENATING COMPLEX POWERED BY MPC™
RALEIGH, N.C. /
Merz Aesthetics Skincare, a division of Merz North America (U.S. affiliate of Merz Pharma Group) today announced the launch of its newest skincare product, MICRO•FIRM™ NECK & DÉCOLLETÉ Rejuvenating Complex by NEOCUTIS®. This advancement in anti-aging skincare was developed to help revitalize skin and improve the appearance of aging on the neck and décolleté. Formulated with Micro Protein Complex (MPC™), this unique peptide blend is the first anti-aging technology to help rejuvenate skin’s elasticity.
-
MERZ AESTHETICS ANNOUNCES KEY DATA PRESENTATIONS AT THE AMERICAN ACADEMY OF DERMATOLOGY MEETING. Data highlights overall commitment to continued development in aesthetics
RALEIGH, N.C. /
Merz Aesthetics, a division of Merz North America (US affiliate of the global Merz Pharma Group) announced today that it will be presenting 13 posters at the annual American Academy of Dermatology Meeting this weekend in Washington D.C.
-
MERZ NEUROSCIENCES ANNOUNCES NATIONWIDE AVAILABILITY OF NEW 200-UNIT VIAL OF XEOMIN® (incobotulinumtoxinA). New Vial Size Supports Adult Upper Limb Spasticity Indication
RALEIGH, N.C. /
Merz Neurosciences, a division of Merz North America (U.S. affiliate of the global Merz Pharma Group), today announced the nationwide availability of Xeomin® (incobotulinumtoxinA) in a 200-unit single-dose vial.